Breaking News

NSF Acquires IPEC Auditing Arm

By Kristin Brooks | February 10, 2014

Adds auditing and certification of excipients

NSF International has acquired the auditing subsidiary of the International Pharmaceutical Excipients Council of the Americas (IPEA). NSF-IPEA can now provide excipient auditing and certification as part of NSF’s Health Sciences Pharma Biotech Division. Clients can also obtain excipient, food additive and dietary supplement ingredient audits from NSF.
The audits require excipients to be safe, functional, and to comply with GMP requirements. The excipient GMP certification program is accredited by the American National Standards Institute (ANSI), and offers third-party audits based on IPEC – PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients and excipient GMP certification.
Additionally, NSF International is working with representatives from the chemical and pharma industries and the FDA to develop an NSF/ANSI excipient GMP consensus standard, which defines GMPs for excipient manufacture for use in drug products and specifies the components of a quality management system for excipient manufacture.
NSF Health Sciences Pharma Biotech vice president Janeen Skutnik-Wilkinson will lead the excipients program. Ms. Skutnik-Wilkinson has more than 20 years of experience in technical and regulatory support roles, including leadership positions with Pfizer, Merck and IPEC, where she played a key role in the creation of IPEA. 
“NSF International shares IPEA’s long-standing commitment to excipient safety. Our expertise in standards development and certification will help excipient manufacturers globally build credibility and save time and money by benefiting from bundled audits and streamlined certification services,” said Ms. Skutnik-Wilkinson.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks